Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
Commentary|Articles|February 2, 2026
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
Author(s)Jax DiEugenio
Fact checked by: Ashling Wahner
Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.
Advertisement
Advertisement
As the
Related to this article
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses CLL17 trial data, resistance mechanisms, and emerging BTK degraders and bispecifics in CLL.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Advertisement
Advertisement